The Effects of Exenatide (Byetta) on Energy Expenditure and Weight Loss in Non-Diabetic Obese Subjects.
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 20 Sep 2016 Status changed from recruiting to completed.
- 11 Mar 2013 Planned end date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 16 Nov 2011 Planned number of patients changed from 100 to 114 as reported by ClinicalTrials.gov.